Cui Ping Gu
Direktor/Vorstandsmitglied bei Refuge Biotechnologies, Inc.
Aktive Positionen von Cui Ping Gu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Hongshan
Hongshan Investment ManagersFinance Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong. | Private Equity Investor | - | - |
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Direktor/Vorstandsmitglied | 02.05.2018 | - |
NuProbe USA, Inc.
NuProbe USA, Inc. Miscellaneous Commercial ServicesCommercial Services NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - | - |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Direktor/Vorstandsmitglied | 01.09.2017 | - |
Silicon INSITE, Inc.
Silicon INSITE, Inc. BiotechnologyHealth Technology Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | - | - |
Shenzhen Jingtai Technology Co., Ltd.
Shenzhen Jingtai Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015. | Direktor/Vorstandsmitglied | - | - |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Cui Ping Gu
Ehemalige bekannte Positionen von Cui Ping Gu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
STRUCTURE THERAPEUTICS INC. | Direktor/Vorstandsmitglied | - | - |
Independent Dir/Board Member | - | - | |
Wuhan Neurophth Biotechnology Co., Ltd.
Wuhan Neurophth Biotechnology Co., Ltd. BiotechnologyHealth Technology Wuhan Neurophth Biotechnology Co., Ltd. is a leading in-vivo gene therapy company for ophthalmic diseases based in Wuhan, China. The Chinese company's core product, nr082 (nfs-01), is designed to treat ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON) and has been granted orphan drug designation (ODD) by the FDA and EMA. It is the first Chinese gene therapy new drug that has been granted IND approval for clinical trials by the Chinese National Medical Products Administration (NMPA) and the FDA. The company's pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic nerve protection, vascular retinopathy, and other preclinical candidates. The company was founded in 2016 by Bin Li, Su Xiao, Dabo Cai, and Bin Li has been the CEO since then. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Cui Ping Gu
Shanghai Jiao Tong University | Undergraduate Degree |
Statistik
International
China | 6 |
Vereinigte Staaten | 5 |
Hong Kong | 2 |
Operativ
Director/Board Member | 8 |
Private Equity Investor | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 5 |
Commercial Services | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
STRUCTURE THERAPEUTICS INC. | Commercial Services |
Private Unternehmen | 8 |
---|---|
Hongshan
Hongshan Investment ManagersFinance Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong. | Finance |
Silicon INSITE, Inc.
Silicon INSITE, Inc. BiotechnologyHealth Technology Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA. | Health Technology |
Shenzhen Jingtai Technology Co., Ltd.
Shenzhen Jingtai Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015. | Commercial Services |
NuProbe USA, Inc.
NuProbe USA, Inc. Miscellaneous Commercial ServicesCommercial Services NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA. | Commercial Services |
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Commercial Services |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Health Technology |
Wuhan Neurophth Biotechnology Co., Ltd.
Wuhan Neurophth Biotechnology Co., Ltd. BiotechnologyHealth Technology Wuhan Neurophth Biotechnology Co., Ltd. is a leading in-vivo gene therapy company for ophthalmic diseases based in Wuhan, China. The Chinese company's core product, nr082 (nfs-01), is designed to treat ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON) and has been granted orphan drug designation (ODD) by the FDA and EMA. It is the first Chinese gene therapy new drug that has been granted IND approval for clinical trials by the Chinese National Medical Products Administration (NMPA) and the FDA. The company's pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic nerve protection, vascular retinopathy, and other preclinical candidates. The company was founded in 2016 by Bin Li, Su Xiao, Dabo Cai, and Bin Li has been the CEO since then. | Health Technology |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | Health Technology |
- Börse
- Insiders
- Cui Ping Gu
- Erfahrung